Scinai Immunotherapeutics Statistics
Total Valuation
SCNI has a market cap or net worth of $1.15 million. The enterprise value is $1.73 million.
| Market Cap | 1.15M |
| Enterprise Value | 1.73M |
Important Dates
The last earnings date was Wednesday, April 1, 2026, before market open.
| Earnings Date | Apr 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SCNI has 3.96 million shares outstanding. The number of shares has increased by 140.86% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.96M |
| Shares Change (YoY) | +140.86% |
| Shares Change (QoQ) | +23.00% |
| Owned by Insiders (%) | 10.51% |
| Owned by Institutions (%) | 3.19% |
| Float | 3.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.99 |
| Forward PS | n/a |
| PB Ratio | 0.19 |
| P/TBV Ratio | 0.20 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.35 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.92 |
Financial Efficiency
Return on equity (ROE) is -29.19% and return on invested capital (ROIC) is -38.62%.
| Return on Equity (ROE) | -29.19% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -38.62% |
| Return on Capital Employed (ROCE) | -56.64% |
| Weighted Average Cost of Capital (WACC) | 11.90% |
| Revenue Per Employee | $26,978 |
| Profits Per Employee | -$70,511 |
| Employee Count | 45 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.86% in the last 52 weeks. The beta is 2.05, so SCNI's price volatility has been higher than the market average.
| Beta (5Y) | 2.05 |
| 52-Week Price Change | -86.86% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.90 |
| Relative Strength Index (RSI) | 29.97 |
| Average Volume (20 Days) | 410,134 |
Short Selling Information
The latest short interest is 97,738, so 2.48% of the outstanding shares have been sold short.
| Short Interest | 97,738 |
| Short Previous Month | 157,814 |
| Short % of Shares Out | 2.48% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.41 |
Income Statement
In the last 12 months, SCNI had revenue of $1.21 million and -$3.17 million in losses. Loss per share was -$1.13.
| Revenue | 1.21M |
| Gross Profit | -4.00M |
| Operating Income | -8.44M |
| Pretax Income | -3.17M |
| Net Income | -3.17M |
| EBITDA | -6.92M |
| EBIT | -8.44M |
| Loss Per Share | -$1.13 |
Balance Sheet
The company has $2.96 million in cash and $3.50 million in debt, with a net cash position of -$533,000 or -$0.13 per share.
| Cash & Cash Equivalents | 2.96M |
| Total Debt | 3.50M |
| Net Cash | -533,000 |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 11.76M |
| Book Value Per Share | 1.73 |
| Working Capital | 929,000 |
Cash Flow
In the last 12 months, operating cash flow was -$6.45 million and capital expenditures -$18,000, giving a free cash flow of -$6.46 million.
| Operating Cash Flow | -6.45M |
| Capital Expenditures | -18,000 |
| Depreciation & Amortization | 1.52M |
| Net Borrowing | n/a |
| Free Cash Flow | -6.46M |
| FCF Per Share | -$1.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | -695.30% |
| Pretax Margin | -261.37% |
| Profit Margin | -261.37% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SCNI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -140.86% |
| Shareholder Yield | -140.86% |
| Earnings Yield | -264.46% |
| FCF Yield | -538.75% |
Analyst Forecast
The average price target for SCNI is $700.00, which is 240,449.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $700.00 |
| Price Target Difference | 240,449.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | 118.93% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 21, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
SCNI has an Altman Z-Score of -10.89. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.89 |
| Piotroski F-Score | n/a |